Please call your physician’s office before coming in for your appointment if you have symptoms of a cough, fever, or difficulty breathing; traveled to Europe or China or other areas impacted by the coronavirus (COVID-19) within the past 14 days; been in close contact with someone who has traveled outside the U.S. to one of the impacted countries; or may have been exposed to the coronavirus. Effective Monday May 18th all VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Our new office hours are: Monday through Friday 8:30 a.m. to 4:00 p.m, if you have an appointment scheduled for after hours, our office will be contacting you directly to reschedule. FOR THE LATEST UP TO DATE INFORMATION, ALERTS AND CANCELLATIONS PLEASE CLICK HERE

VCS Enrolls First Patient in Phase 1/2 Clinical Trial of BION-1301-Novel Anti-APRIL Antibody, Treatment of Multiple Myeloma

Virginia Cancer Specialists Practice Blog

December 28, 2017
Virginia Cancer Specialists » VCS Practice News » Physicians » VCS Practice News » Amit Sarma MD » VCS Enrolls First Patient in Phase 1/2 Clinical Trial of BION-1301-Novel Anti-APRIL Antibody, Treatment of Multiple Myeloma

Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma

Congratulations to Dr. Spira and his study team at the Research Institute for enrolling the first patient.

Data Presented Recently at ASH Demonstrate BION-1301’s Blocking of TACI in Addition to BCMA Results in Inhibition of Regulatory T Cells —

BERKELEY, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the first patient in its Phase 1/2 dose escalation and dose expansion clinical trial (see www.clinicaltrials.gov, identifier NCT03340883) has been dosed at Virginia Cancer Specialists in Fairfax, Virginia, the first site in this multi-center trial. Read the complete Press Release Here